Dose Insider / Outsourcing pharmacies / Leesar Inc.

Leesar Inc.FDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

Leesar Inc. in Fort Myers, Florida is registered with FDA as a 503B outsourcing facility, first on April 30, 2014 and most recently on November 26, 2025. FDA last inspected it on September 28, 2026 and issued a Form 483.

Inspected 2026last FDA inspection September 28, 2026
Facilities registered, by first yearFDA list of November 17, 2026; this facility’s year in coral2019620203202112022420239202415202514202614Facilities registered, byfirst yearFDA list of November 17, 2026; this facility’syear in coral2019620203202112022420239202415202514202614

From FDA’s list of registered outsourcing facilities, November 17, 2026.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilityLeesar Inc.
LocationFort Myers, Florida
Type503B outsourcing facility
Registered sinceApril 30, 2014
Latest registrationNovember 26, 2025
Last FDA inspectionSeptember 28, 2026
Inspection dates—
Form 483Issued
FDA action after the inspectionOpen
Compounds sterile drugs from bulkNo
FDA warning letters on GLP-1 drugs0

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

16 of the 100 facilities on FDA’s list are in Florida. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Registered outsourcing facilities: inspection status of Leesar Inc.. fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider